Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial by Cohen, Jeffrey A, Dr, Arnold, Douglas L, MD, Comi, Giancarlo, MD, Bar-Or, Amit, MD, Gujrathi, Sheila, MD, Hartung, Jeffrey P, PhD, Cravets, Matt, MA, Olson, Allan, MD, Frohna, Paul A, MD, Selmaj, Krzysztof W, MD

Get full text

An open-label, 6-month study of allopurinol safety in gout: The LASSO study by Becker, Michael A., MD, Fitz-Patrick, David, MD, Choi, Hyon K., MD, PhD, Dalbeth, Nicola, MD, FRACP, Storgard, Chris, MD, Cravets, Matt, MA, MBA, Baumgartner, Scott, MD

Get full text

TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension by Frantz, Robert P., Benza, Raymond L., Channick, Richard N., Chin, Kelly, Howard, Luke S., McLaughlin, Vallerie V., Sitbon, Olivier, Zamanian, Roham T., Hemnes, Anna R., Cravets, Matt, Bruey, Jean-Marie, Roscigno, Robert, Mottola, David, Elman, Erin, Zisman, Lawrence S., Ghofrani, Hossein-Ardeschir

Get full text

Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects by Ottoboni, Tom, Lauw, Michael, Keller, Mary Rose, Cravets, Matt, Manhard, Kimberly, Clendeninn, Neil, Quart, Barry

Get full text

Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation by Ottoboni, Tom, Keller, Mary Rose, Cravets, Matt, Clendeninn, Neil, Quart, Barry

Get full text

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma... by Soussain, Carole, Issa, Samar, Lewis, Katharine L, Grommes, Christian, Fox, Judith, Ward, Renee, Peterson, Caryn, Cravets, Matt, Mathias, Anita, Sosa, Judith, Kirby, Brian J, Ding, Zhaoqing, Yusuf, Isharat, Rose, Mark J, Steinberg, Marcos W, Tun, Han W.

Get full text

Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects by Kirby, Brian J, Aranda, Richard, Ward, Renee, Steinberg, Marcos W, Hernandez, Maria, Sosa, Judith, Cravets, Matt, Rose, Mark J, Osterhout, Robin, Ding, Zhaoqing, Yusuf, Isharat, Fox, Judith, Mathias, Anita

Get full text

HTX-019 via 2-min injection or 30-min infusion in healthy subjects by Ottoboni, Thomas, Lauw, Michael, Keller, Mary Rose, Cravets, Matt, Manhard, Kimberly, Clendeninn, Neil, Quart, Barry

Get full text

Bioequivalence of HTX-019 by Keller, Mary Rose, Quart, Barry, Ottoboni, Tom, Clendeninn, Neil, Cravets, Matt

Get full text

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY P... by Soussain, Carole, Grommes, Christian, Issa, Samar, Ward, Renee, Peterson, Caryn, Cravets, Matt, Mathias, Anita, Sosa, Judith, Kirby, Brian, Ding, Zhaoqing, Yusuf, Isharat, Rose, Mark, Steinberg, Marcos, Tun, Han W

Get full text

445 The TOUCHSTONE Study: a Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis by Sandborn, William, Feagan, Brian G, Wolf, Douglas C, D'Haens, Geert R, Vermeire, Severine, Hanauer, Stephen B, Ghosh, Subrata, Smith, Heather, Cravets, Matt, Frohna, Paul A, Gujrathi, Sheila, Olson, Allan

Get full text